Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$WPRT Westport Innovations: We Expect Shares To Remain Rangebound, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/31/westport-innovations-we-expect-shares-to-remain-rangebound-says-deutsche-bank/
$AEGR Aegerion: Deutsche Bank Questioned Management's Ability To Execute http://www.smarteranalyst.com/2014/10/31/aegerion-deutsche-bank-questioned-managements-ability-to-execute/
$AEGR Aegerion: Deutsche Bank Questioned Management's Ability To Execute http://www.smarteranalyst.com/2014/10/31/aegerion-deutsche-bank-questioned-managements-ability-to-execute/
$SGEN H.C. Wainwright Maintains Buy On Seattle Genetics On The Back Of 3Q Growth http://www.smarteranalyst.com/2014/10/31/h-c-wainwright-maintains-buy-on-seattle-genetics-on-the-back-of-3q-growth/
$PPHM Peregrine Pharma: We View The Risk/Reward Profile As Favorable, Says Roth Capital http://www.smarteranalyst.com/2014/10/31/peregrine-pharma-we-view-the-riskreward-profile-as-favorable-says-roth-capital/
$PPHM Peregrine Pharma: We View The Risk/Reward Profile As Favorable, Says Roth Capital http://www.smarteranalyst.com/2014/10/31/peregrine-pharma-we-view-the-riskreward-profile-as-favorable-says-roth-capital/
$BCRX Roth Capital Maintains Buy On BioCryst Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/31/roth-capital-maintains-buy-on-biocryst-ahead-of-3q14-results/
$EXPE Cantor Assigns Buy On Expedia Following Earnings http://www.smarteranalyst.com/2014/10/31/cantor-assigns-buy-on-expedia-following-earnings/
$EXPE Cantor Assigns Buy On Expedia Following Earnings http://www.smarteranalyst.com/2014/10/31/cantor-assigns-buy-on-expedia-following-earnings/
$LNKD Cantor Remains Bullish On LinkedIn On The Back Of Strong 3Q14 Results; Raises PT To $255 http://www.smarteranalyst.com/2014/10/31/cantor-remains-bullish-on-linkedin-on-the-back-of-strong-3q14-results-raises-pt-to-255/
$LNKD Cantor Remains Bullish On LinkedIn On The Back Of Strong 3Q14 Results; Raises PT To $255 http://www.smarteranalyst.com/2014/10/31/cantor-remains-bullish-on-linkedin-on-the-back-of-strong-3q14-results-raises-pt-to-255/
$SGYP Cantor Maintains Buy On Synergy Pharmaceuticals, Reduced PT To $8 http://www.smarteranalyst.com/2014/10/30/cantor-maintains-buy-on-synergy-pharmaceuticals-reduced-pt-to-8/
$ANIP Oppenheimer Sets Expectations On ANI Pharmaceuticals Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/30/oppenheimer-sets-expectations-on-ani-pharmaceuticals-ahead-of-3q14-results/
$CRUS Cirrus Logic: We Continue To See Valuation Extended At These Levels, Says Oppenheimer http://www.smarteranalyst.com/2014/10/30/cirrus-logic-we-continue-to-see-valuation-extended-at-these-levels-says-oppenheimer/
$FB Facebook: Future Remains Bright, Says Wedbush; Maintains Outperform http://www.smarteranalyst.com/2014/10/30/facebook-future-remains-bright-says-wedbush-maintains-outperform/
$FB Facebook: Future Remains Bright, Says Wedbush; Maintains Outperform http://www.smarteranalyst.com/2014/10/30/facebook-future-remains-bright-says-wedbush-maintains-outperform/
$NPSP Wedbush Sets Expectations On NPS Pharmaceuticals Heading Into Q314 Earnings Release http://www.smarteranalyst.com/2014/10/30/wedbush-sets-expectations-on-nps-pharmaceuticals-heading-into-q314-earnings-release/
$GILD Maxim Group Maintains Buy On Gilead Sciences; Sees 15% Upside For The Stock http://www.smarteranalyst.com/2014/10/29/maxim-group-maintains-buy-gilead-sciences-sees-15-upside-stock/
$GILD Maxim Group Maintains Buy On Gilead Sciences; Sees 15% Upside For The Stock http://www.smarteranalyst.com/2014/10/29/maxim-group-maintains-buy-gilead-sciences-sees-15-upside-stock/
$BABA Deutsche Bank Becomes Bullish On Alibaba Shares; Sees 15% Upside For The Stock http://www.smarteranalyst.com/2014/10/29/deutsche-bank-becomes-bullish-alibaba-shares-sees-15-upside-stock/
$BABA Deutsche Bank Becomes Bullish On Alibaba Shares; Sees 15% Upside For The Stock http://www.smarteranalyst.com/2014/10/29/deutsche-bank-becomes-bullish-alibaba-shares-sees-15-upside-stock/
$FB Facebook: A Little Ice Bucket Dumped On The Bull-Case, But We’re Still Warm, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/29/facebook-little-ice-bucket-dumped-bull-case-still-warm-says-deutsche-bank/
$FB Facebook: A Little Ice Bucket Dumped On The Bull-Case, But We’re Still Warm, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/29/facebook-little-ice-bucket-dumped-bull-case-still-warm-says-deutsche-bank/
$INVN We Recommend Accumulation Of InvenSense Shares, Says Roth Capital; Reduces PT To $25 http://www.smarteranalyst.com/2014/10/29/recommend-accumulation-invensense-shares-says-roth-capital-reduces-pt-25/
$INVN We Recommend Accumulation Of InvenSense Shares, Says Roth Capital; Reduces PT To $25 http://www.smarteranalyst.com/2014/10/29/recommend-accumulation-invensense-shares-says-roth-capital-reduces-pt-25/
$INVN InvenSense: Our Fear Of Potential Margin Pressure Came To Be With Nightmarish Force, Says Oppenheimer http://www.smarteranalyst.com/2014/10/29/invensense-fear-potential-margin-pressure-came-nightmarish-force-says-oppenheimer/
$INVN InvenSense: Our Fear Of Potential Margin Pressure Came To Be With Nightmarish Force, Says Oppenheimer http://www.smarteranalyst.com/2014/10/29/invensense-fear-potential-margin-pressure-came-nightmarish-force-says-oppenheimer/
$FB Oppenheimer Remains Bullish On Facebook But Slightly Reduced PT To $88 http://www.smarteranalyst.com/2014/10/29/oppenheimer-remains-bullish-facebook-slightly-reduced-pt-88/
$FB Oppenheimer Remains Bullish On Facebook But Slightly Reduced PT To $88 http://www.smarteranalyst.com/2014/10/29/oppenheimer-remains-bullish-facebook-slightly-reduced-pt-88/
$APRI Cantor Moves To The Sideline On Apricus Shares; Cuts PT To $1.50 http://www.smarteranalyst.com/2014/10/28/cantor-moves-sideline-apricus-shares-cuts-pt-1-50/
$TWTR Twitter: We Would Use Weakness To Add To Positions, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/28/twitter-use-weakness-add-positions-says-deutsche-bank/
$TWTR Twitter: We Would Use Weakness To Add To Positions, Says Deutsche Bank http://www.smarteranalyst.com/2014/10/28/twitter-use-weakness-add-positions-says-deutsche-bank/
$BWLD Oppenheimer Reiterates Perform On Buffalo Wild Wings As Earnings Growth Slows http://www.smarteranalyst.com/2014/10/28/oppenheimer-reiterates-perform-buffalo-wild-wings-earnings-growth-slows/
$BWLD Oppenheimer Reiterates Perform On Buffalo Wild Wings As Earnings Growth Slows http://www.smarteranalyst.com/2014/10/28/oppenheimer-reiterates-perform-buffalo-wild-wings-earnings-growth-slows/
$EXAS Roth Capital Maintains Buy On Exact Sciences Following 3Q Update http://www.smarteranalyst.com/2014/10/28/roth-capital-maintains-buy-exact-sciences-following-3q-update/
$SRPT Roth Capital Remains Positive On Sarepta Following NDA Submission Delay http://www.smarteranalyst.com/2014/10/28/roth-capital-remains-positive-sarepta-following-nda-submission-delay/
$SRPT Roth Capital Remains Positive On Sarepta Following NDA Submission Delay http://www.smarteranalyst.com/2014/10/28/roth-capital-remains-positive-sarepta-following-nda-submission-delay/
$LGND Cantor Reduces Ligand Pharmaceuticals Price Target Following 3Q14 Results http://www.smarteranalyst.com/2014/10/28/cantor-reduces-ligand-pharmaceuticals-price-target-following-3q14-results/
$TWTR UPDATE: Cantor Remains Buyers Of Twitter Following Earnings http://www.smarteranalyst.com/2014/10/28/update-cantor-remains-buyers-twitter-following-earnings/
$TWTR UPDATE: Cantor Remains Buyers Of Twitter Following Earnings http://www.smarteranalyst.com/2014/10/28/update-cantor-remains-buyers-twitter-following-earnings/